NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
April 22, 2011
NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Lung Cancer Study Highlights Current Limitations of MALDI Mass Spec
July 22, 2011 / ProteoMonitor - Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test
April 15, 2011 / ProteoMonitor - Glycomics Firm Sialix Developing Auto Antibody-Based Tests for Breast, Colon, Prostate Cancers
April 29, 2011 / ProteoMonitor - NYU, Somalogic Present Data on Protein Biomarker Test for Mesothelioma
April 8, 2011 / ProteoMonitor - SomaLogic Launching Validation and Prospective Trials for Protein Biomarker Lung Cancer Diagnostic
December 10, 2010 / ProteoMonitor